Bad Blood

NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.<BR><BR>“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review<BR><BR>In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.

'A story so incredible you'd think it was fiction' - James Patterson<BR><BR>Winner of the Financial Times/McKinsey Business Book of the Year Award.<BR><BR>The shocking true story of the breathtaking rise and collapse of Theranos, the multibillion-dollar biotech startup founded by Elizabeth Holmes. Written by the prize-winning journalist who first broke the shocking story and pursued it to the end.<BR><BR>'I couldn't put down this thriller . . . a book so compelling that I couldn't turn away' - Bill Gates<BR><BR>Seen as the female Steve Jobs, Theranos founder and CEO Elizabeth Holmes was a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by wealthy investors, Theranos sold shares that valued the company at more than $9 billion.<BR><BR>There was just one problem: the technology didn't work . . .<BR><BR>Despite threats of legal action, brave whistleblowers started to talk. They revealed a culture of intimidation and secrecy, technology that repeatedly failed, results sent to real patients that were incorrect but upon which life-changing medical decisions were being made, with devastating consequences.<BR><BR>The riveting story behind The Dropout, in Bad Blood, John Carreyrou investigates the biggest corporate fraud since Enron, a tale of ambition and scandal set amid the bold promises of Silicon Valley.<BR><BR>'A tale of corporate fraud and legal browbeating that reads like a crime thriller' - TIME, The 10 Best Nonfiction Books of the Year

NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.<BR><BR>“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review<BR><BR>In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.